세계의 뇌수막염균 감염증 백신 시장 보고서(2025년)

Meningococcal Disease Vaccine Global Market Report 2025

US $ 4,490 ￦ 6,233,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,010,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,786,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

뇌수막염균 감염증 백신 시장 규모는 향후 몇 년 동안 급속한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 예방 의료에 대한 인식의 제고, 대상 연령대의 확대, 새로운 시장 참여자의 진입, 잠재적인 발병에 대비한 정부 및 보건 기관의 비축 조치, 공공 교육 노력의 강화에 기인할 수 있습니다. 이 기간 동안 예상되는 주요 동향으로는 백신 기술의 발전, 다중, 복합 및 단백질 기반 백신의 개발, 여행 및 이주에 대한 세계의적 동향, mRNA 기술에 대한 연구 및 개발의 증가, 열 안정성 백신 제형의 혁신 등이 있습니다.

뇌수막염균 감염증 백신 시장의 성장은 정부 예방 접종 프로그램의 증가에 의해 촉진되고 있습니다. 이러한 프로그램은 전염병으로부터 인구를 보호하기 위해 무료 또는 저렴한 백신을 제공하는 공중 보건 이니셔티브입니다. 이러한 프로그램의 확대는 질병 예방에 대한 관심의 강화와 광범위한 예방 접종 노력을 통한 의료 시스템의 부담 경감에서 기인합니다. 백신 접근성 향상과 예방접종률 증가는 공공 인식 제고와 질병 발생률 감소에 기여합니다. 또한 예방접종 의무화 및 공중 보건 캠페인을 통해 수요를 창출합니다. 예를 들어, 2024년 4월 미국에 본부를 두고 있는 전문 기관인 범미주 보건기구(PAHO)는 “현재 참여하여 미래를 보호하세요”라는 주사제로 제22회 아메리카 예방접종 주간(VWA)을 발족했습니다. GetVax"라는 주사제로 제22회 미주 예방 접종 주간을 시작했습니다. 이 캠페인은 6,500만 회 이상의 백신을 접종하여, 특히 의료 서비스가 부족한 지역 사회에서 백신 접종률을 높이는 것을 목표로 했습니다. 이 캠페인은 잘못된 정보를 바로잡고, 지역 사회 홍보 활동과 맞춤형 캠페인을 통해 백신 접근성을 개선하는 데 중점을 두었습니다. 그 결과, 정부의 예방 접종 노력이 확대되면서 뇌수막염균 감염증 백신 시장이 성장하고 있습니다.

뇌수막염균 감염증 백신 시장의 주요 업체들은 혈청형 보호 범위를 확대하고, 예방 접종 일정을 간소화하며, 질병 예방을 강화하기 위해 5가 제제 등 첨단 백신의 개발에 주력하고 있습니다. 5가 뇌수막염균 감염증 백신은 Neisseria meningitidis의 5가지 주요 혈청형에 대한 예방 접종을 1회 접종으로 제공하여, 여러 번의 접종 필요성을 최소화하고 백신 준수율을 높입니다. 예를 들어, 2023년 10월, 미국에 본사를 둔 바이오 제약 회사인 Pfizer Inc.는 10-25세 개인을 대상으로 뇌수막염균 질환 예방을 위해 승인된 최초이자 유일한 백신인 PENBRAYA에 대해 FDA의 승인을 받았습니다. 이 획기적인 백신은 Trumenba와 Nimenrix라는 두 가지 기존 백신의 요소를 결합하여 세계의 침습성 뇌수막염균 질환(IMD) 사례의 대부분을 유발하는 Neisseria meningitidis의 5가지 가장 흔한 혈청형(A, B, C, W, Y)를 예방합니다. 이 세균은 세계의 침습성 뇌수막염균 질환(IMD) 사례의 대부분을 차지합니다. PENBRAYA는 미국에서 판매되는 백신 중 가장 광범위한 혈청군을 커버하고, 완전한 예방을 위해 필요한 총 투여 횟수를 줄일 가능성이 있어 질병 예방에 큰 도약을 의미합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 뇌수막염균 감염증 백신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 뇌수막염균 감염증 백신 시장 : 성장률 분석
• 세계의 뇌수막염균 감염증 백신 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 뇌수막염균 감염증 백신 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 뇌수막염균 감염증 백신 총 시장 규모(TAM)

제6장 시장 세분화

• 세계의 뇌수막염균 감염증 백신 시장 : 백신 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 결합형 백신
• 다당체 백신
• 재조합 백신
• 약독생 백신
• 세계의 뇌수막염균 감염증 백신 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 유아
• 어린이
• 성인
• 고령자
• 세계의 뇌수막염균 감염증 백신 시장 : 적응증별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 예방 백신 접종
• 노출 후 예방
• 여행 관련 백신 접종
• 아웃브레이크 대응
• 세계의 뇌수막염균 감염증 백신 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 약국
• 소매 약국
• 온라인 약국
• 기타
• 세계의 뇌수막염균 감염증 백신 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 전문 클리닉
• 가정
• 기타
• 세계의 뇌수막염균 감염증 백신 시장 : 결합형 백신 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 1가
• 4가
• 소아용
• 청소년기/성인용
• 세계의 뇌수막염균 감염증 백신 시장 : 다당체 백신 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 2가
• 3가
• 4가
• 연령 특이적
• 세계의 뇌수막염균 감염증 백신 시장 : 재조합 백신 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 혈청군 B
• 다성분
• 외막 소포(OMV) 베이스
• 세계의 뇌수막염균 감염증 백신 시장 : 약독생 백신 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 실험적 비강
• 유전자 재조합
• 혼합

제7장 지역별, 국가별 분석

• 세계의 뇌수막염균 감염증 백신 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 뇌수막염균 감염증 백신 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 뇌수막염균 감염증 백신 시장 : 경쟁 구도
• 뇌수막염균 감염증 백신 시장 : 기업 프로파일
  • Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
  • GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Hualan Biological Engineering Inc.
• Beijing Tiantan Biological Products Corporation Limited
• Serum Institute of India Pvt. Ltd.
• Walvax Biotechnology Co. Ltd.
• Incepta Pharmaceuticals Ltd.
• CanSino Biologics Inc.
• EuBiologics Co. Ltd.
• Biovac Institute
• Shantha Biotech
• Bio-Manguinhos
• Biomed Pvt. Ltd.
• Chengdu Kanghua Biological Products Co. Ltd.
• Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
• Finlay Institute of Vaccines
• Immunopreparat

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 뇌수막염균 감염증 백신 시장(2029년) : 새로운 기회를 제공하는 국가
• 뇌수막염균 감염증 백신 시장(2029년) : 새로운 기회를 제공하는 부문
• 뇌수막염균 감염증 백신 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

The meningococcal disease vaccine is designed to protect against meningococcal disease, a severe bacterial infection caused by Neisseria meningitidis. This illness can result in meningitis, which is the inflammation of the membranes surrounding the brain and spinal cord, as well as septicemia, a serious bloodstream infection both of which can be life-threatening.

There are several main types of meningococcal vaccines conjugate vaccines, polysaccharide vaccines, recombinant vaccines, and live attenuated vaccines. Conjugate vaccines work by linking bacterial sugars to proteins, thereby enhancing the immune response and providing effective protection against serogroups A, C, W, and Y. These vaccines are particularly recommended for adolescents and individuals at higher risk. They are available for a range of age groups, including infants, children, adults, and the elderly, and are used for various purposes such as routine prevention, post-exposure prophylaxis, travel immunization, and in response to outbreaks. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others, with end-users comprising hospitals, specialty clinics, home care services, and additional healthcare settings.

The meningococcal disease vaccines market research report is one of a series of new reports from The Business Research Company that provides meningococcal disease vaccines market statistics, including the meningococcal disease vaccines industry global market size, regional shares, competitors with the meningococcal disease vaccines market share, detailed meningococcal disease vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the meningococcal disease vaccines industry. This meningococcal disease vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The meningococcal disease vaccine market size has grown rapidly in recent years. It will grow from$2.37 billion in 2024 to $2.62 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to enhanced vaccine manufacturing capabilities, the establishment of global health partnerships, incorporation into national immunization programs, an increase in meningococcal disease cases, and intensified efforts by various organizations.

The meningococcal disease vaccine market size is expected to see rapid growth in the next few years. It will grow to$3.83 billion in 2029 at a compound annual growth rate (CAGR) of 10.0%. The growth projected for the forecast period can be attributed to rising awareness of preventive healthcare, the expansion of target age groups, the entry of new market participants, stockpiling initiatives by governments and health agencies in preparation for potential outbreaks, and increasing public education efforts. Key trends expected during this period include advancements in vaccine technology, the development of multivalent, conjugate, and protein-based vaccines, global trends in travel and migration, increased research and development in mRNA technology, and innovations in thermostable vaccine formulations.

The growth of the meningococcal disease vaccine market is being driven by the rise in government immunization programs. These programs are public health initiatives that provide free or affordable vaccines to protect populations against infectious diseases. The expansion of these programs stems from a stronger focus on disease prevention and reducing the burden on healthcare systems through widespread vaccination efforts. By increasing access to vaccines and boosting immunization rates, these programs help raise public awareness and lower disease incidence. They also generate demand through vaccination mandates and public health campaigns. For example, in April 2024, the Pan American Health Organization (PAHO), a US-based specialized agency, launched the 22nd Vaccination Week in the Americas (VWA) under the theme "Engage now to protect your future. GetVax." The campaign aimed to boost vaccine coverage, particularly in underserved communities, by administering over 65 million doses. The initiative targeted misinformation and improved vaccine access through community outreach and customized campaigns. As a result, growing government immunization efforts are fueling the expansion of the meningococcal disease vaccine market.

Leading players in the meningococcal disease vaccine market are focusing on the development of advanced vaccines, such as pentavalent formulations, to broaden serogroup protection, simplify vaccination schedules, and enhance disease prevention. A pentavalent meningococcal vaccine offers immunization against five major serogroups of Neisseria meningitidis in a single dose, minimizing the need for multiple injections and improving vaccine compliance. For instance, in October 2023, Pfizer Inc., a US-based biopharmaceutical firm, received FDA approval for PENBRAYA, the first and only vaccine approved for preventing meningococcal disease in individuals aged 10 to 25 years. This groundbreaking vaccine merges elements from two existing vaccines, Trumenba and Nimenrix, to safeguard against the five most common serogroups (A, B, C, W, and Y) of Neisseria meningitidis, which are responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. PENBRAYA marks a major leap in disease prevention by offering the widest serogroup coverage among U.S.-available vaccines and potentially reducing the total number of required doses for complete protection.

In September 2023, Biovac, a biopharmaceutical company based in South Africa, joined forces with EuBiologics Co. Ltd. to enhance Africa's capacity for vaccine innovation and self-reliance. This collaboration is focused on technology transfer and the local production of a pentavalent meningococcal conjugate vaccine in Africa. The initiative seeks to meet urgent healthcare demands in the meningitis belt and promote regional vaccine manufacturing capabilities. EuBiologics Co., Ltd., based in South Korea, specializes in the production of pentavalent meningococcal conjugate vaccines.

Major players in the meningococcal disease vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, Novartis AG, GlaxoSmithKline plc, Hualan Biological Engineering Inc., Beijing Tiantan Biological Products Corporation Limited, Serum Institute of India Pvt. Ltd., Walvax Biotechnology Co. Ltd., Incepta Pharmaceuticals Ltd., CanSino Biologics Inc., EuBiologics Co. Ltd., Biovac Institute, Shantha Biotech, Bio-Manguinhos, Biomed Pvt. Ltd., Chengdu Kanghua Biological Products Co. Ltd., Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd., Finlay Institute of Vaccines, and Immunopreparat.

North America was the largest region in the meningococcal disease vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in meningococcal disease vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the meningococcal disease vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The meningococcal disease vaccine market consists of sales of protein-based vaccines, outer membrane vesicle (OMV) vaccines, and multicomponent vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Meningococcal Disease Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on meningococcal disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for meningococcal disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The meningococcal disease vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Vaccine Type: Conjugate Vaccines; Polysaccharide Vaccines; Recombinant Vaccines; Live Attenuated Vaccines
• 2) By Age Group: Infants; Children; Adults; Older Adults
• 3) By Indication: Preventive Vaccination; Post-Exposure Prophylaxis; Travel-Related Vaccination; Outbreak Response
• 4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
• 5) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Conjugate Vaccines: Monovalent Conjugate Vaccines; Quadrivalent Conjugate Vaccines; Pediatric Conjugate Vaccines; Adolescent Or Adult Conjugate Vaccines
• 2) By Polysaccharide Vaccines: Bivalent Polysaccharide Vaccines; Trivalent Polysaccharide Vaccines; Quadrivalent Polysaccharide Vaccines; Age-Specific Polysaccharide Formulations
• 3) By Recombinant Vaccines: Serogroup B Recombinant Protein Vaccines; Multicomponent Recombinant Vaccines; Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
• 4) By Live Attenuated Vaccines: Experimental Intranasal Live Attenuated Vaccines; Genetically Engineered Attenuated Strain Vaccines; Combined Live Attenuated Vaccines
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Meningococcal Disease Vaccine Market Characteristics

3. Meningococcal Disease Vaccine Market Trends And Strategies

4. Meningococcal Disease Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Meningococcal Disease Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Meningococcal Disease Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Meningococcal Disease Vaccine Market Growth Rate Analysis
• 5.4. Global Meningococcal Disease Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Meningococcal Disease Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Meningococcal Disease Vaccine Total Addressable Market (TAM)

6. Meningococcal Disease Vaccine Market Segmentation

• 6.1. Global Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conjugate Vaccines
• Polysaccharide Vaccines
• Recombinant Vaccines
• Live Attenuated Vaccines
• 6.2. Global Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infants
• Children
• Adults
• Older Adults
• 6.3. Global Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Vaccination
• Post-Exposure Prophylaxis
• Travel-Related Vaccination
• Outbreak Response
• 6.4. Global Meningococcal Disease Vaccine Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Other Distribution Channels
• 6.5. Global Meningococcal Disease Vaccine Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Homecare
• Other End-Users
• 6.6. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monovalent Conjugate Vaccines
• Quadrivalent Conjugate Vaccines
• Pediatric Conjugate Vaccines
• Adolescent Or Adult Conjugate Vaccines
• 6.7. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Polysaccharide Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bivalent Polysaccharide Vaccines
• Trivalent Polysaccharide Vaccines
• Quadrivalent Polysaccharide Vaccines
• Age-Specific Polysaccharide Formulations
• 6.8. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Recombinant Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serogroup B Recombinant Protein Vaccines
• Multicomponent Recombinant Vaccines
• Outer Membrane Vesicle (OMV) Based Recombinant Vaccines
• 6.9. Global Meningococcal Disease Vaccine Market, Sub-Segmentation Of Live Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Experimental Intranasal Live Attenuated Vaccines
• Genetically Engineered Attenuated Strain Vaccines
• Combined Live Attenuated Vaccines

7. Meningococcal Disease Vaccine Market Regional And Country Analysis

• 7.1. Global Meningococcal Disease Vaccine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Meningococcal Disease Vaccine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Meningococcal Disease Vaccine Market

• 8.1. Asia-Pacific Meningococcal Disease Vaccine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Meningococcal Disease Vaccine Market

• 9.1. China Meningococcal Disease Vaccine Market Overview
• 9.2. China Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Meningococcal Disease Vaccine Market

• 10.1. India Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Meningococcal Disease Vaccine Market

• 11.1. Japan Meningococcal Disease Vaccine Market Overview
• 11.2. Japan Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Meningococcal Disease Vaccine Market

• 12.1. Australia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Meningococcal Disease Vaccine Market

• 13.1. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Meningococcal Disease Vaccine Market

• 14.1. South Korea Meningococcal Disease Vaccine Market Overview
• 14.2. South Korea Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Meningococcal Disease Vaccine Market

• 15.1. Western Europe Meningococcal Disease Vaccine Market Overview
• 15.2. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Meningococcal Disease Vaccine Market

• 16.1. UK Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Meningococcal Disease Vaccine Market

• 17.1. Germany Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Meningococcal Disease Vaccine Market

• 18.1. France Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Meningococcal Disease Vaccine Market

• 19.1. Italy Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Meningococcal Disease Vaccine Market

• 20.1. Spain Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Meningococcal Disease Vaccine Market

• 21.1. Eastern Europe Meningococcal Disease Vaccine Market Overview
• 21.2. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Meningococcal Disease Vaccine Market

• 22.1. Russia Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Meningococcal Disease Vaccine Market

• 23.1. North America Meningococcal Disease Vaccine Market Overview
• 23.2. North America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Meningococcal Disease Vaccine Market

• 24.1. USA Meningococcal Disease Vaccine Market Overview
• 24.2. USA Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Meningococcal Disease Vaccine Market

• 25.1. Canada Meningococcal Disease Vaccine Market Overview
• 25.2. Canada Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Meningococcal Disease Vaccine Market

• 26.1. South America Meningococcal Disease Vaccine Market Overview
• 26.2. South America Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Meningococcal Disease Vaccine Market

• 27.1. Brazil Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Meningococcal Disease Vaccine Market

• 28.1. Middle East Meningococcal Disease Vaccine Market Overview
• 28.2. Middle East Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Meningococcal Disease Vaccine Market

• 29.1. Africa Meningococcal Disease Vaccine Market Overview
• 29.2. Africa Meningococcal Disease Vaccine Market, Segmentation By Vaccine Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Meningococcal Disease Vaccine Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Meningococcal Disease Vaccine Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Meningococcal Disease Vaccine Market Competitive Landscape And Company Profiles

• 30.1. Meningococcal Disease Vaccine Market Competitive Landscape
• 30.2. Meningococcal Disease Vaccine Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Meningococcal Disease Vaccine Market Other Major And Innovative Companies

• 31.1. Hualan Biological Engineering Inc.
• 31.2. Beijing Tiantan Biological Products Corporation Limited
• 31.3. Serum Institute of India Pvt. Ltd.
• 31.4. Walvax Biotechnology Co. Ltd.
• 31.5. Incepta Pharmaceuticals Ltd.
• 31.6. CanSino Biologics Inc.
• 31.7. EuBiologics Co. Ltd.
• 31.8. Biovac Institute
• 31.9. Shantha Biotech
• 31.10. Bio-Manguinhos
• 31.11. Biomed Pvt. Ltd.
• 31.12. Chengdu Kanghua Biological Products Co. Ltd.
• 31.13. Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.
• 31.14. Finlay Institute of Vaccines
• 31.15. Immunopreparat

32. Global Meningococcal Disease Vaccine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Meningococcal Disease Vaccine Market

34. Recent Developments In The Meningococcal Disease Vaccine Market

35. Meningococcal Disease Vaccine Market High Potential Countries, Segments and Strategies

• 35.1 Meningococcal Disease Vaccine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Meningococcal Disease Vaccine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Meningococcal Disease Vaccine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료